Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily in the CNS, reducing prostaglandin synthesis; analgesic and antipyretic. Oxycodone: mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception.
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Management of moderate to moderately severe pain,Acute pain,Chronic pain
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
1-2 tablets (equivalent to 325-650 mg acetaminophen / 5-10 mg oxycodone) every 4-6 hours as needed for pain; maximum 12 tablets per day (acetaminophen limit 3900 mg/day or lower if hepatic risk).
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment or overdose); Oxycodone: 3-5 hours (immediate-release), 4.5-8 hours (extended-release); Clinical context: Terminal half-life of oxycodone may be prolonged in elderly or patients with renal/hepatic impairment.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Acetaminophen: primarily hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1), and minor CYP450 (CYP2E1, CYP3A4) to toxic NAPQI. Oxycodone: hepatic via CYP3A4 (major) and CYP2D6 (minor) to active metabolites (noroxycodone, oxymorphone).
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Acetaminophen: renal excretion of metabolites (glucuronide 45-55%, sulfate 20-30%, cysteine and mercapturate conjugates 5-10%) and unchanged drug (<5%); Oxycodone: renal excretion of unchanged drug (approximately 10-19%) and metabolites (noroxycodone, oxymorphone, and their glucuronides) (total renal elimination ~60-87%); fecal elimination of Oxycodone is minimal (<10%).
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
Acetaminophen: 20-30% (albumin); Oxycodone: 45-50% (albumin).
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
Acetaminophen: 0.9-1.0 L/kg (suggests distribution into total body water); Oxycodone: 2.6-4.0 L/kg (suggests extensive tissue distribution).
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
Acetaminophen: Oral 85-90%; Oxycodone: Oral 60-87% (first-pass metabolism), Rectal (oxycodone suppository) ~60-80%.
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
e GFR 30-60 m L/min: start with 50% of usual dose, increase cautiously; e GFR <30 m L/min: start with 25% of usual dose, extend dosing interval to every 8-12 hours; avoid in dialysis due to oxycodone accumulation.
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: start with 50% of usual dose, maximum acetaminophen 2000 mg/day; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
Weight-based: oxycodone 0.05-0.15 mg/kg/dose (max 5 mg/dose) with acetaminophen 10-15 mg/kg/dose every 4-6 hours; maximum acetaminophen 75 mg/kg/day (not to exceed 4000 mg/day).
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Start with lowest dose (e.g., half of adult dose), titrate slowly; avoid in patients with impaired renal/hepatic function or those at risk for falls; monitor for respiratory depression and constipation.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen may cause hepatotoxicity; neonatal opioid withdrawal syndrome; CYP3A4 interaction with benzodiazepines or other CNS depressants.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
Addiction, abuse, misuse; respiratory depression; accidental exposure; neonatal opioid withdrawal syndrome; hepatotoxicity (acetaminophen); interactions with CNS depressants; elderly or debilitated patients; renal impairment; severe hypotension; adrenal insufficiency; use in patients with head injury.
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
Hypersensitivity to acetaminophen or oxycodone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction (e.g., paralytic ileus); severe hepatic impairment; concurrent use with MAOIs or within 14 days.
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
Avoid alcohol. Grapefruit juice may increase oxycodone levels; limit or avoid grapefruit products. High-fat meals may delay absorption of oxycodone. Maintain adequate hydration to prevent constipation.
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
Acetaminophen: Generally considered low risk; no consistent association with major malformations. Oxycodone: First trimester: No increased risk of major malformations in human studies. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use; respiratory depression at delivery. No specific human data for combination; extrapolated from individual components.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
Acetaminophen: Compatible; M/P ratio ~1.0 (low transfer). Oxycodone: Low levels in milk; M/P ratio ~3.6 (relative infant dose 1.7–6.3% of maternal weight-adjusted dose). Monitor infant for drowsiness, respiratory depression. Use lowest effective dose, shortest duration.
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
Acetaminophen: No dose adjustment needed; use lowest effective dose. Oxycodone: Pharmacokinetic changes in pregnancy include increased clearance (due to enhanced hepatic metabolism and renal blood flow) and increased volume of distribution, potentially reducing plasma concentrations. Dose may need to be increased (monitor for efficacy and avoid withdrawal); however, use lowest effective dose to minimize neonatal risks. Consider non-opioid alternatives.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen intake should not exceed 4000 mg. Oxycodone has high abuse potential; consider prescribing naloxone for patients at risk of opioid overdose. Avoid concurrent use of other CNS depressants. Use with caution in elderly or renally impaired patients.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
Do not exceed 4000 mg of acetaminophen per day from all sources.,This medication can cause drowsiness; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol while taking this medication.,Take exactly as prescribed; do not crush, chew, or break extended-release tablets.,Store securely out of reach of children and dispose of unused medication properly.,Seek emergency medical attention if you experience difficulty breathing, severe drowsiness, or signs of an allergic reaction.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
"Phenobarbital, a potent inducer of cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2D6, significantly increases the hepatic metabolism of oxycodone, a prodrug that requires CYP3A4-mediated N-demethylation to noroxycodone and CYP2D6-mediated O-demethylation to oxymorphone for its analgesic effects. This induction reduces the systemic exposure and peak plasma concentration of active oxycodone and its active metabolite oxymorphone, leading to diminished analgesic efficacy and potential opioid withdrawal symptoms in patients on chronic opioid therapy. Clinically, patients may require substantially higher doses of oxycodone to achieve pain relief, increasing the risk of dose-related adverse effects if the interaction is not recognized."
"The co-administration of oxycodone, a mu-opioid receptor agonist, and gamma-hydroxybutyric acid (GHB), a central nervous system depressant with activity at GABA-B and GHB receptors, results in additive or synergistic respiratory depression and CNS depression. This interaction potentiates the risk of severe hypoventilation, coma, and fatal overdose, especially in non-tolerant users or at therapeutic doses. The combined sedation also increases the likelihood of hypotension, bradycardia, and impaired psychomotor function, necessitating extreme caution."
"The coadministration of oxycodone, a mu-opioid receptor agonist with central nervous system (CNS) depressant effects, and perampanel, a noncompetitive AMPA receptor antagonist that also causes CNS depression, produces additive sedative and respiratory depressant effects. This synergy increases the risk of excessive sedation, impaired cognitive function, and potentially life-threatening respiratory depression. Patients may experience profound somnolence, confusion, and an increased fall risk, necessitating dose adjustments or avoidance."
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE, answered by our medical review team.
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily in the CNS, reducing prostaglandin synthesis; analgesic and antipyretic. Oxycodone: mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception.. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE and ACETAMINOPHEN AND HYDROCODONE BITARTRATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is: 1-2 tablets (equivalent to 325-650 mg acetaminophen / 5-10 mg oxycodone) every 4-6 hours as needed for pain; maximum 12 tablets per day (acetaminophen limit 3900 mg/day or lower if hepatic risk).. The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE and ACETAMINOPHEN AND HYDROCODONE BITARTRATE. Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Oxycodone. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent association with major malformations. Oxycodone: First trimester: No increased risk of major malformations in human stud. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.